Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update

Gossamer Bio, Inc. (NASDAQ:GOSS) was the target of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 6,300,000 shares, a decrease of 9.4% from the October 15th total of 6,950,000 shares. Based on an average daily trading volume, of 810,000 shares, the days-to-cover ratio is presently 7.8 days.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Price Performance

Shares of Gossamer Bio stock traded down $0.02 during trading on Monday, reaching $0.72. 597,580 shares of the company’s stock were exchanged, compared to its average volume of 1,430,347. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. Gossamer Bio has a 1-year low of $0.50 and a 1-year high of $1.60. The company has a market cap of $163.17 million, a P/E ratio of -2.25 and a beta of 1.96. The firm’s 50-day moving average price is $0.93 and its 200 day moving average price is $0.87.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $9.48 million during the quarter, compared to the consensus estimate of $4.52 million. As a group, research analysts anticipate that Gossamer Bio will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Gossamer Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC increased its holdings in shares of Gossamer Bio by 51.6% during the first quarter. Acadian Asset Management LLC now owns 2,736,385 shares of the company’s stock worth $3,227,000 after buying an additional 931,248 shares in the last quarter. Marshall Wace LLP raised its position in Gossamer Bio by 170.8% in the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock valued at $3,002,000 after purchasing an additional 2,103,766 shares during the last quarter. NEA Management Company LLC raised its position in Gossamer Bio by 14.2% in the second quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock valued at $16,300,000 after purchasing an additional 2,255,025 shares during the last quarter. Monaco Asset Management SAM boosted its stake in shares of Gossamer Bio by 390.3% during the second quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock valued at $2,456,000 after purchasing an additional 2,170,104 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its holdings in shares of Gossamer Bio by 27.2% during the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock worth $84,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.